AUS
NZ
UK
CA
USA
IND
Owning shares in companies that are not yet profitable can be lucrative, as evidenced by Cardiol Therapeutics (TSX:CRDL), which has seen a remarkable 136% increase in its share price over the past year. This impressive gain highlights the potential for financial reward in the healthcare sector, though it also brings attention to the inherent risks associated with unprofitable businesses.
To assess the sustainability of Cardiol Therapeutics' financial health, a closer look at its cash burn is essential. Cash burn refers to the amount of cash a company expends annually to support its operations and growth, which in this context is synonymous with negative free cash flow. Evaluating the company's cash burn relative to its cash reserves helps in understanding its cash runway—how long it can continue operating before needing additional funding.
Trends in Cash Burn
Cardiol Therapeutics has not reported any revenue over the last year, reflecting its early-stage development phase. In the absence of sales data, observing the trend in cash burn provides insight into the company's expenditure patterns. Notably, the company has managed to reduce its cash burn by 27% over the past year, which indicates a measure of financial prudence. Despite this improvement, the primary concern remains the company's ability to maintain its operations in the future.
Future Capital Requirements
Although the recent reduction in cash burn is a positive sign, assessing the company's ability to raise additional funds is crucial. Companies typically secure funding through debt or equity. For Cardiol Therapeutics, this could involve issuing new shares or securing loans. Analyzing the company's annual cash burn relative to its market capitalization—CA$219 million in this case—reveals that the CA$22 million burned last year represents only 9.8% of its market value. This relatively modest proportion suggests that raising further capital, whether through new shares or loans, could be feasible.
Assessment of Financial Stability
Cardiol Therapeutics' current cash burn scenario appears manageable. The reduction in cash burn coupled with a strong market capitalization provides a favorable outlook. Furthermore, forecasts indicate that the company might achieve breakeven in the near future. While concerns about cash-burning companies are valid, the metrics reviewed in this context suggest that Cardiol Therapeutics is in a relatively stable position.
In conclusion, while Cardiol Therapeutics shows promising signs with its reduced cash burn and manageable market capitalization ratio, continued vigilance is necessary. The company’s ability to sustain its financial health while pursuing growth opportunities will be key in evaluating its long-term
